United States Adopted Names Council - Recently adopted name for antitumoral compound (December 2011) - Nom d’antitumoral adopté récemment (décembre 2011)

Name (nom)	Code name (nom de code)	Type	Target(s) (Cible(s))
Elotuzumab	BMS-901608 HuLuc63	antibody (anticorps)	SLAM family member 7 (CD2-like receptor activating cytotoxic cells, CD319 antigen), CS1

According to National Cancer Institute (NCI) Drug Dictionary, elotuzumab is a humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.

See also: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862628/pdf/nihms167262.pdf